Medicrea (EPA:ALMED) announced that the U.S. Patent Office recently issued the artificial intelligence spinal surgery developer seven new patents related to its UNiD adaptive spine intelligence (ASI) technology platform.
The UNiD ASI is designed to use artificial intelligence to enhance clinical and surgical workflow, increase reproducibility, improve surgical outcomes and expand the potential for surgeons. The platform is designed to allow the surgeon to plan cases in the pre-operation stage, with the AI providing a way to visualize mechanisms above and below the spine that will most likely occur based on the surgical plan.
Medicrea said it is continuing to actively develop IP protection for its technology with an aggressive patent strategy, which has produced a portfolio consisting of 13 U.S. patents so far, along with more throughout the world.
The company’s seven new patents are directed to fundamental technologies and methods embedded in the UNiD ASI platform, according to a news release. Medicrea said it plans to expand its existing patent portfolio and the latest patents enable it to do so.
The company has been and continues to actively develop IP protection for these innovations through an aggressive patent strategy, resulting in an IP portfolio that now includes 13 US issued patents as well as others throughout the world.
“With over 5,000 cases performed through the UNiD ASI technology platform, all including patient-specific implants, this technology undoubtedly met a market need,” Medicrea founder & CEO Denys Sournac said in the release. “The new U.S. patents issued create strong barriers to entry for competitors. It enables the company to maintain its competitive advantage and strengthen its leading position in the marketplace that is now obviously evolving into this direction.”